Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trialEunice S. Wang, Amir T. Fathi, Ghayas C. Issa et al.|The Lancet Oncology|2024Cited by 106
AML-732: Ziftomenib Combined With Intensive Induction Chemotherapy (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia (AML): Updated Phase 1a/b Results From KOMET-007Amer M. Zeidan, Harry P. Erba, Suresh Kumar Balasubramanian et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 3
POSTER: AML-732 Ziftomenib Combined With Intensive Induction Chemotherapy (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia (AML): Updated Phase 1a/b Results From KOMET-007Amer M. Zeidan, Harry P. Erba, Eunice S. Wang et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0